Clenbuterol to Target DUX4 in FSHD

计划入组 30 人 · 首次发布于 2024 年 12 月 6 日

Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1

计划入组 60 人 · 首次发布于 2023 年 11 月 15 日

Global collaboRAtion on CIC-DUX4, BCOR-CCN3, High-grade Undifferentiated Round Cell Sarcoma (URCS) Project

计划入组 260 人 · 首次发布于 2022 年 5 月 3 日

ARO-DUX4

DUX4 inhibitors, Idera Pharmaceuticals

DUX4 inhibitor (facioscapulohumeral dystrophy)

Protein Sciences Corporation

United States

HOUSE OF SUPPLEMENTS AUSTRALIA PTY LTD

Australia

Sanofi-Aventis Deutschland Gmbh

Sweden

Avidity Biosciences' Del-brax Trial Enrolls New Cohort for Accelerated FSHD Approval

Epicrispr Biotechnologies Doses First Patient with EPI-321, Novel Epigenetic Therapy for Facioscapulohumeral Muscular Dystrophy

Arrowhead Pharmaceuticals Receives $100 Million Milestone Payment for ARO-DM1 Myotonic Dystrophy Treatment